BUZZ-Aeterna Zentaris Inc: Biggest percentage gainer on Nasdaq
** Canadian drug developer's U.S.-listed shares jump 29 pct to $4.90; stock top percentage gainer on Nasdaq
** Aeterna signs a license agreement to market its cancer drug, Zoptrex, in Australia and New Zealand with privately held Specialised Therapeutics Asia
** Zoptrex is currently undergoing a late-stage trial for the treatment of endometrial cancer
** More than 3.9 mln shares traded, 28.2x their 30-day moving avg; stock's busiest day since July 1
** Up to Wednesday's close, stock had fallen 15.2 pct this year
© Thomson Reuters 2017 All rights reserved.